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Abstract
16 S-[2,3-bis(palmitoyl)propyl]cysteine (Pam2) lipopeptides act as toll-like receptor (TLR)2/6 ligands and activate natural
killer (NK) cells and dendritic cells (DCs) to produce inflammatory cytokines and cytotoxic NK activity in vitro. However, in
this study, we found that systemic injection of Pam2 lipopeptides was not effective for the suppression of NK-sensitive B16
melanomas in vivo. When we investigated the immune suppressive mechanisms, systemic injection of Pam2 lipopeptides
induced IL-10 in a TLR2-dependent manner. The Pam2 lipopeptides increased the frequencies of Foxp3
+CD4
+ regulatory T
(T reg) cells in a TLR2- and IL-10- dependent manner. The T reg cells from Pam2-lipopeptide injected mice maintained
suppressor activity. Pam2 lipopeptides, plus the depletion of T reg with an anti-CD25 monoclonal antibody, improved
tumor growth compared with Pam2 lipopeptides alone. In conclusion, our data suggested that systemic treatment of Pam2
lipopeptides promoted IL-10 production and T reg function, which suppressed the effective induction of anti-tumor
immunity in vivo. It is necessary to develop an adjuvant that does not promote IL-10 and T reg function in vivo for the future
establishment of an anti-cancer vaccine.
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Introduction
Foxp3
+CD25
+CD4
+regulatory T (T reg) cells constitute about
5–10% of peripheral CD4
+T cells and control immunological self-
tolerance and tumor immunity [1,2]. T reg cells directly infiltrate
the tumor and suppress effector cells [3–5]. T reg cells are also
induced from non-T reg cells in the draining lymph nodes of
tumor-bearing mice by transforming growth factor (TGF)-b
producing dendritic cells (DCs) [6]. Effective anti-tumor immunity
is induced by depletion of T reg cells with anti-CD25 monoclonal
antibody (mAb) [7–9], or blockade of T reg function with anti-
CTLA-4 mAb [10–12] or anti-GITR mAb [3]. Specific depletion
of T reg cells using mice that express diphtheria toxin receptor
under the control of the Foxp3 locus induced tumor regression
[4,13]. Therefore, strategies are required to abolish the T reg-
induced tolerance that suppresses tumor immunity, thereby
establishing an effective anti-tumor immune response.
To overcome the immune suppression mediated by T reg cells
in cancer, activation of DCs with adjuvants is required [14,15].
Adjuvants are mainly targeted to pattern recognition receptors,
such as Toll like receptor (TLR) ligands on DCs. To date, cancer
vaccine adjuvants have included various TLR agonists such as
TLR3, TLR4, TLR5, TLR7 and TLR9 [16,17]. DCs stimulated
by lipopolysaccharide (LPS), a TLR4 agonist, were found to
expand functional T reg cells [18,19]. Hence, it is critical to
identify the optimal adjuvants that mature DCs but have less
potential to expand T reg cells. However, it is unclear how
adjuvants differently affect T reg cell survival and function.
The Bacillus Calmette-Guerin-cell wall skeleton (BCG-CWS) is
a TLR2 agonist [20] and has been used as an effective adjuvant
for cancer for almost 40 years [16,21]. However, its clinical usage
is limited since BCG-CWS is a large molecular complex unable
to be chemically synthesized with full activity. The anti-cancer
activity of BCG-CWS operates partly through TLR2 signal [22–
24], hence, we investigated the adjuvant activity of synthetic
TLR2/TLR6 ligands derived from Staphylococcus aureus, 16 S-[2,3-
bis(palmitoyl)propyl]cysteine (Pam2) lipopeptides. We have pre-
viously reported that Pam2 lipopeptides activate DCs and natural
killer (NK) cells to produce interferon (IFN)- c and killer activity
in vitro [25] and that local injection of Pam2 lipopetides with
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[26].
Here, we tested if systemic injection of Pam2 lipopeptides in
mice could induce an effective anti-tumor immune response. The
Pam2 lipopeptides have two palmitoyl-bases attached to different
peptide sequences (Fig. 1A) and the peptide portion determines
the activity of the TLR2 agonist [25]. We selected the most
effective TLR2 activators among the 20 Pam2 lipopeptides [25]
and investigated the corresponding anti-tumor response in vivo.
In contrast with the in vitro results, systemic injection of Pam2
lipopeptides did not induce regression of NK-sensitive melano-
mas. Pam2 lipopeptides induced IL-10 and the expansion of T
reg cells in vivo in a TLR2-dependent manner. We also found
that the depletion of T reg cells by treatment with an anti-CD25
mAb before Pam2 lipopeptide injection, suppressed the tumor
growth compared with Pam2-lipopeptide injection alone. These
data suggested that systemic injection of Pam2 lipopeptides
induced IL-10 and T reg cells, preventing effective tumor
immunity in vivo. Our findings demonstrate the importance of
studying the effects on T reg cells in vivo prior to the development
of adjuvants.
Results
Systemic injection of Pam2 lipopeptides did not induce
tumor growth retardation
To examine the anti-tumor effect of the Pam2 lipopeptides in
vivo, mice were injected subcutaneously (s.c.) with NK-sensitive
B16D8 melanomas into their back [22] and were treated with
Pam2 lipopeptides twice a week (Fig. 1B). We selected four kinds
of Pam2 lipopeptides, as shown in Fig. 1A, because they strongly
activated NK cells through DCs and induced cytotoxic activity in
vitro [25]. To our surprise, although the Pam2 lipopeptides
activated NK cells in vitro [25], we did not observe effective anti-
tumor response in vivo (Fig. 1B). To exclude the possibility that
Pam2 lipopeptides were not distributed systemically, we investi-
gated the activation of spleen DCs and NK cells by flow
cytometry. The injection of Pam2 lipopeptides up-regulated
CD86 and CD40 on splenic DCs (Fig. 1C). Similarly, CD69
was up-regulated in splenic NK cells (Supplemental Fig. S1). Thus,
systemic injection of Pam2 lipopeptides was able to activate DCs
and NK cells in the spleen, but did not induce effective anti-tumor
responses in vivo.
Pam2 lipopeptides induce IL-10 in vitro and in vivo in a
TLR2-dependent manner
To investigate why Pam2 lipopeptides could not induce effective
anti-tumor responses against NK-sensitive tumors in vivo,w e
investigated whether Pam2 lipopeptides could activate suppressive
factors, such as IL-10 and T reg -related molecules. For this
experiment, we mainly used a representative Pam2 lipopeptide,
Pam2CSK4, since Pam2CSK4 could activate DCs as well as other
tested Pam2 lipopeptides in vitro [25].
When the mRNA levels from DCs stimulated with or without
Pam2 lipopeptides were analyzed, Pam2 lipopeptides up-regulated
retinal dehydrogenase 2 (RALDH2) and IL-10. RALDH2 in DCs
activates retinoic acid, which is an important cofactor for TGF-b1
to induce Foxp3 [27,28]. However, Pam2 lipopeptides did not up-
regulate the mRNA of TGF-b1 (Fig. 2A).
To confirm whether IL-10 protein is produced from DCs, we
stimulated DCs with Pam2 lipopeptides in vitro for 24 hours and
the concentration of IL-10 in the supernatants was measured
by the ELISA. Bone-marrow derived DCs (BM-DCs) stimulated
by Pam2 lipopeptides produced IL-10 (Fig. 2B). IL-10 was
also produced by Pam2 lipopeptide-stimulated DCs from the
spleen (data not shown). When DCs from TLR2- knockout
(TLR2KO) mice were cultured with Pam2 lipopeptides, the
production of IL-10 was not detected (Fig. 2B). Hence, IL-10
production was TLR2 dependent. Interestingly, we also found
that Pam2 lipopeptides induced IL-10 production from NK cells
(Fig. 2C).
To determine whether CD4
+ T cells produced IL-10 in the
presence of Pam2 lipopeptides, OT II ovalbumin (OVA)
transgenic CD4
+ T cells were cultured with DCs along with
various doses of OVA peptide, with or without Pam2 lipopeptides
(Fig. 2D). In the presence of Pam2 lipopeptides, more IL-10 was
produced in the culture supernatants when OT II CD4
+ T cells
were cultured with DCs and antigen (Fig. 2D). Importantly, IL-10
production was increased in an antigen-dose dependent manner
(Fig. 2D).
Next, we analyzed the concentration of IL-10 in the serum of
Pam2 lipopeptide-treated mice (Fig. 2E). When serum was taken
at one day after Pam2CSK4 injection, significant amounts of IL-
10 were detected (Fig. 2E), however, Th1, Th2 and Th17
cytokines were not detected (Fig. 2E). IL-10 production in serum
was confirmed to be TLR2 dependent because we could not detect
IL-10 in Pam2CSK4-treated TLR2KO mice (Fig. 2E). Taken
together, these results indicated that Pam2 lipopeptides induce IL-
10 both in vitro and in vivo in a TLR2-dependent manner, which
might play a role in suppressing tumor immunity induced by
Pam2 lipopeptides.
Systemic injection of Pam2 lipopeptides expands T reg
cells through the TLR2 dependent production of IL-10
Since Pam2 lipopeptides induce IL-10, we investigated whether
systemic injection of Pam2 lipopeptides could affect T reg cell
frequencies. IL-10 produced by zymosan plays a role in inducing
T reg cells [29]. We found that the frequency of Foxp3
+ T reg was
increased in the spleen and lymph nodes at day 3 after systemic
injection of Pam2CSK4 (Fig. 3A). The frequency of T reg cells
had returned to normal by day 7 after Pam2CSK4 injection
(Supplemental Fig. S2). The increase of T reg cells was dependent
on TLR2 because T reg cells were not increased in TLR2KO
mice injected with Pam2CSK4 (Fig. 3B).
To investigate whether the increase of Foxp3
+ T reg is
dependent on the IL-10 produced by Pam2CSK4, mice were
injected with neutralizing anti-IL-10 mAb (JES5-2A5) and
Pam2CSK4 (Fig. 3C). Control mice injected with anti-IL-10
mAb alone or untreated mice were not included in this
experiment, however, the frequency of Foxp3
+ T reg cells in the
mice injected with anti-IL-10 Ab alone would be expected be
similar to that of naı ¨ve mice since it is reported that the frequency
of Foxp3
+ T reg cells is not affected in the spleen of IL-10 [30] or
IL-10 receptor b knockout mice [31]. After three days, co-
administration of anti-IL-10 mAb blocked the increase of T reg
cells after Pam2CSK4 injection (Fig. 3C).
Therefore, Pam2 lipopeptides expand Foxp3
+ T reg cells at day
3 after systemic injection in a TLR2- and IL-10 dependent
manner.
T reg cells from Pam2 lipopeptide-treated mice have
suppressive activity
Next, we investigated the suppressive function of T reg cells in
Pam2 lipopeptide-treated mice. We purified CD25
+CD4
+ T cells
from naive mice or Pam2 lipopeptide-treated mice by flow
cytometry (Fig. 4A). The frequency of Foxp3
+CD4
+ T cells in the
purified CD25
+CD4
+ T cells from naı ¨ve mice or Pam2
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The purified CD25
+CD4
+ T cells were used for the classical in
vitro suppression assay [32]. We found that the CD25
+ T reg cells
from Pam2CSK4-treated mice suppressed the proliferation of
CD25
- CD4
+ T cells from naı ¨ve mice to a similar degree
compared with the CD25
+ T reg from naı ¨ve mice (Fig. 4B, C).
This indicated that Pam2 lipopeptides maintain T reg cell
function in vivo.
Depletion of T reg cells improves the anti-tumor
response by systemic injection of Pam2 lipopeptides
To determine whether systemic injection of Pam2 lipopeptides
activates the function of T reg cells and suppresses anti-tumor
responses against NK-sensitive tumors in vivo, we used an anti-
CD25mAb (PC61) to deplete T reg cells in vivo before challenge
with Pam2 lipopeptide and tumor cells [7–9]. Mice were injected
with anti-CD25 mAb on day 23 and challenged with B16D8
melanoma cells on day 0, with or without Pam2CSK4 (Fig. 5A).
As previously reported, depletion of T reg cells alone induced
growth retardation of tumors [7–9]. Tumor growth was slightly
promoted by Pam2CSK4 injection alone (Fig. 5A). However, the
tumor growth in mice treated with anti-CD25 mAb plus
Pam2CSK4 was slower than in mice treated with Pam2CSK4
alone (Fig. 5A, B). These results suggested that the presence of T
reg cells suppressed effective anti-tumor responses after systemic
injection of Pam2 lipopeptides.
Figure 1. Pam2 lipopeptides do not induce effective anti-tumor immunity. (A) Structures of the Pam2 lipopeptides are shown. (B) Mice
were injected with B16D8 melanoma cells (2610
5) on back. The mice were injected s.c. into their footpad with the indicated Pam2 lipopeptides
(10 nmol) or saline twice a week, as indicated by arrows, starting from day 0. Tumor growth was monitored in a blind manner. A cross indicates the
death of one mouse. One of two experiments is shown. (C) Mice were injected with the indicated Pam2 lipopeptides (10 nmol) or saline. After 12–
16 hours, spleen DCs were analyzed by flow cytometry. Plots were gated on CD11c
+ cells. One of two experiments is shown.
doi:10.1371/journal.pone.0018833.g001
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Pam2CSK4 or Pam2-#12. After four hours, total RNA was prepared and real-time PCR was performed. Expression of each sample was normalized to
GAPDH mRNA expression and fold increases of each sample were calculated to the expression levels at 0 hours. One of two experiments is shown. (B)
BM-DCs (1610
5) from wild type (WT) or TLR2KO mice were cultured with or without 100 nM of Pam2-#6, Pam2-#12 and Pam2CSK4 for 24 hours. The
culture supernatants were measured for IL-10. One of two experiments is shown. (C) NK cells (2610
5) from spleens were cultured with 100 nM of
Pam2-#6, Pam2-#12 and Pam2CSK4 for 24 hours. The culture supernatants were measured for IL-10. One of two experiments is shown. (D) OT II
CD4
+ T cells (5610
4) were cultured with spleen DCs (5610
4) with or without 100 nM of Pam2CSK4 or Pam2-#12 and the various doses of OVA
peptide. After five days, supernatants were measured for IL-10. The means +/- SDs from two separate experiments is shown. (E) WT or TLR2KO mice
were i.p. injected with 10 nmol Pam2CSK4 and next day serum was measured for the indicated cytokine concentrations.
doi:10.1371/journal.pone.0018833.g002
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Here, we showed that systemic injection of Pam2 lipopeptides
did not induce effective tumor immunity presumably because of
the induction of IL-10 and T reg cells. To treat cancer, it is
necessary to develop new adjuvants to activate immunity in
immune-suppressed patients. Adjuvant activity is generally
screened by analyzing its effect on effector cells such as NK cells
and CD8
+ cytotocxic T cells. However, our results indicated that it
is also important to investigate the activity of adjuvants on
suppressive factors, such as IL-10 and T reg cells, particularly in
vivo.
IL-10 is a key cytokine for IL-10 producing Tr1 regulatory T
cells [33], and has also been shown to be an important cytokine for
Foxp3
+ T reg cells. IL-10 production by Foxp3
+ T reg cells is
required for the prevention of colitis [34,35]. The specific deletion
of IL-10 in Foxp3
+ T reg cells in mice induces inflammation
especially in the intestine, indicating that IL-10 derived from T reg
cells plays a critical role in controlling colitis [35]. Furthermore,
M. Kronenberg and his colleagues recently found that IL-10
secreted by other cells is needed for T reg cells to sustain
expression of Foxp3 and prevent colitis [31]. This indicated that
IL-10-enriched environments are preferable for Foxp3
+ T reg cells
to exert their suppressive function in vivo. Here we have shown that
systemic injection of Pam2 lipopeptides induces IL-10-rich
environments in vivo, which could play a role in promoting T reg
cell function.
Our results showed that TLR2-dependent production of IL-10
plays a role in expanding T reg cells in vivo (Fig. 3). This is
consistent with a recent report by B. Pulendran and his colleagues
who showed that TLR2 signaling by zymosan induces IL-10 and
retinal dehydrogenase in DCs, which are critical for inducing T
reg cells [29]. Zymosan binds to TLR2 and dectin-1 [29]. Our
data showed that the TLR2 signal induced by Pam2 lipopeptides
has a similar effect to the signal induced by zymosan. The TLR2
signal induced by zymosan results in the active suppression of
experimental autoimmune encephalomyelitis (EAE) [29]. Further-
more, various TLR signals prevent the development of autoim-
mune type 1 diabetes in non-obese diabetic mice [36]. Our results
showed that systemic injection of Pam2 lipopeptides was
ineffective at inducing tumor immunity. However, it is possible
that the Pam2 lipopeptides might be useful to inducing tolerance
in the case of autoimmunity, allergy or transplant rejection.
In addition to the evidence that IL-10 produced in response to
the TLR2 signal affects Foxp3
+ T reg cell function, the TLR2
signal can also directly act on T reg cells and promotes their
survival [37]. Taken all together, although TLR2 activation by
Pam2 lipopeptides is able to induce inflammatory cytokines and
activate NK cells in vitro [25], the systemic injection of Pam2
lipopeptides as cancer adjuvants is ineffective at abolishing
immune suppression. Whereas, the effective cancer adjuvant,
BCG-CWS, activates not only TLR2, but also TLR4 and NOD2
receptors [23,38]. TLR2 activation by Pam2 lipopeptides could
activate T reg cells in vivo and the T reg cells could suppress NK
function and activation [39–41]. Our preliminary experiments
showed that T reg cells actually suppress IFN-c production from
NK cells stimulated with DCs plus Pam2CSK4 (S.Y., K.O., T.S.,
unpublished data). Here we showed that depletion of T reg cells
with adjuvant might be one potential strategy to cancel the effect
of activating suppressive factors by Pam2 lipopeptides.
We also found that Pam2 lipopeptides induce IL-10 production
from NK cells in vitro (Fig. 2C). It has been known for over a
decade that NK cells produce IL-10 [42–44]. Recent reports
showed that IL-10 produced by NK cells play an important role in
controlling T cell responses [45,46] and anti-inflammatory
responses [47]. Moreover, IL-10 enhances the killing by NK cells
of autologous antigen presenting cells [48,49]. These reports
suggested that IL-10-stimulated NK cells could kill autologous
macrophages and DCs, which may result in suppressing effective
anti-tumor immunity. Therefore, it is possible that systemic
injection of Pam2 lipopeptides in our system may induce IL-10
from NK cells and suppress anti-tumor response in vivo.
In contrast to the systemic injection of Pam2 lipopeptides, local
injection of Pam2 lipopeptides was effective at suppressing tumor
growth when the Pam2 lipopeptide was fused to RGDS-integrin
peptides and injected around the tumor with tumor extracts [26].
This was probably effective for a few reasons:1) the peptide part of
the Pam2 lipopeptide was fused with RGDS, which could promote
the binding of Pam2 lipopeptides to DCs; 2) local injection of
Pam2 lipopeptides around the tumor may be different from
systemic injection of Pam2 lipopeptides in terms of inducing IL-10
and T reg cells. Other literature has also indicated that local
administration of Pam2 lipopeptides could be effective for cancer
[50,51]. The differential effect on inducing IL-10 and T reg cells
between local administration and systemic injection of adjuvants
should be investigated further in future studies.
The literature on TLR2 signaling and T reg cells is
controversial. Some groups reported that T reg cells temporally
lost their suppressive capacity in the presence of the TLR2/TLR1
ligand Pam3CSK4, which contains 3-palmitoyl bases [52,53].
However, a recent report from E. Shevach and his colleagues
showed that the presence of Pam3CSK4 in the culture actually
maintained the suppressive function of T reg cells and promoted
their survival [37]. This discrepancy might be caused by the use of
CD25
+ CD4
+ T cells contaminated with Foxp3
-CD25
+CD4
+ T
cells, and Foxp3-GFP reporter mice [37]. Contamination of
Foxp3
-CD25
+CD4
+ T cells could affect the results, especially
when TLR2 ligands were continuously present in the culture, since
TLR2 is also expressed on activated effector T cells. In this report,
we stimulated T reg cells with Pam2 lipopeptides in vivo and
purified T reg cells as CD25
+ CD4
+ T cells because Foxp3-GFP
reporter mice were not available. However, CD25
+ CD4
+ T reg
cells purified from Pam2CSK4 treated mice were as suppressive as
T reg cells from naı ¨ve mice (Fig. 4B). This indicated that T reg
cells stimulated by TLR2 did not reverse the suppressive function
in vivo.
To fight to cancer, it is very important to develop an adjuvant to
activate immunity. However, it is also crucial to consider the effect
of adjuvants on suppressive factors such as IL-10 and T reg cells.
The combination of adjuvant and blockade of IL-10 or T reg cell
function might prove a successful strategy for improving cancer
vaccines.
Figure 3. Systemic injection of Pam2CSK4 expands Foxp3
+ T reg cells in a TLR2- and IL-10-dependent manner. (A) WT mice were i.p.
injected with Pam2CSK4 (10 nmol). After three days, spleen (Sp) and lymph node (LN) cells were analyzed for the expression of Foxp3. The plots were
gated on CD4
+ T cells. One of four experiments is shown for the FACS plots. The image summarizes the results of four separate experiments. P value
is derived from the student’s-t test. (B) As in (A), but TLR2KO mice were injected with Pam2CSK4. One of two experiments is shown for the FACS plots.
The image summarizes the results from two separate experiments. N.s. stands for not significant according to the student’s-t test. (C) As in (A), but
mice were i.p. injected with Pam2CSK4 with or without 200 mg of anti-IL-10 mAb. One of two experiments is shown.
doi:10.1371/journal.pone.0018833.g003
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Mice
C57BL6J (B6) mice and CB17SCID mice were obtained from
Japan Clea (Tokyo, Japan). TLR2KO mice were provided by
Dr. Shizuo Akira (Osaka University, Osaka, Japan). OT II OVA
CD4 transgenic mice were kindly provided from Dr. Kazuya
Iwabuchi (Kitasato University, Kanagawa, Japan). The mice
were maintained in the Hokkaido University Animal Facility
(Sapporo, Japan) in specific pathogen free condition. All
Figure 4. T reg cells from Pam2CSK4-treated mice maintain suppressive activity. (A)CD25
+CD4
+ T cells purified by flow cytometry were
further fixed and stained with Foxp3. FACS plots were gated on CD4
+ T cells. One of three similar experiments is shown.(B) B6 mice were i.p. injected
with Pam2CSK4 (10 nmol) on days 0, 3 and 7. On day 14, CD25
+CD4
+ T cells purified as in (A) were used for the suppression assay. CFSE-labeled CD25
-
CD4
+ T cells (5610
4) were stimulated with irradiated spleen antigen presenting cells (1610
5) with or without 5% anti-CD3 mAb supernatant. The
purified CD25
+CD4
+ T cells from naı ¨ve mice or Pam2CSK4-treated mice were added at the indicated ratio. After three days, cells were stained with
CD4 and analyzed with CFSE dilution. Dead cells were eliminated by TOPRO-3. One of three similar experiments is shown. (C) As in (B), but the
numbers of live CFSE
+ CD4
+T cells per culture were plotted. One of three similar experiments is shown.
doi:10.1371/journal.pone.0018833.g004
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the time of first procedure. All mice were used according to the
guidelines of the institutional animal care and use committee of
the Hokkaido University, who approved this study as ID
number: 08-0243, ‘‘ Analysis of immune modulation by toll-
like receptors’’.
Antibodies and reagents
PE-conjugated CD25 (PC61), Alexa-488 conjugated anti-CD25
(7D4), FITC or APC conjugated CD4 (RM4-5), CD11c, NK1.1,
purified anti-CD16/CD32 (2.4G2), purified anti-CD3 (2C11), and
isotype antibodies were obtained from Biolegend (San Diego, CA,
USA). Anti-CD11c, anti-NK and streptavidin microbeads were
purchased from Miltenyi Biotec (Gladbach, Germany). Carboxy-
fluorescein diacetate succinimidyl ester (CFSE) and TOPRO-3
were from Molecular Probes (Eugene, OR, USA). The anti-mouse
Foxp3 (FJK-16s) staining kit was from eBioscience (San Diego,
CA, USA). Purified anti-CD25 (PC61) mAb was a gift from Dr.
Ralph Steinman (The Rockefeller University, NY, USA) and anti-
CD25 hybridoma cells were from Dr. Jun Shimizu (Kyoto
University, Kyoto, Japan). Some of the anti-CD25 (PC61) mAb
was produced in CB17SCID mice in our animal facility and
purified by ammonium sulfate precipitation. Purified anti-IL-10
mAb (JES5-2A5) was prepared as described previously [54].
Pam2CSK4, Pam2CSK2 and MALP2 short lipopeptides were
synthesized by Biologica Co. Ltd (Nagoya, Japan). Pam2-#6 and
Pam2-#12 were from Dr. Yukari Fujimoto and Dr. Koichi Fukase
(Osaka University, Osaka, Japan).
Cell isolations
CD4
+ T cells were first negatively separated by MACS beads
from lymph nodes and spleen cell suspensions (.90%) (Miltenyi
Biotech) and T reg cells were further purified by a FACS Aria II
(BD Bioscience, Franklin Lakes, NJ, USA). Spleen CD11c
+ DCs
were selected with anti-CD11c beads (Miltenyi Biotech). Bone
marrow DCs (BM-DCs) were cultured with GM-CSF as
previously described [22]. NK cells were purified from spleen by
anti-NK beads (Miltenyi Biotech). To analyze the activation of
DCs and NK cells in vivo by Pam2 lipopeptides, 10 nmol of Pam2
lipopeptides was subcutaneously (s.c.) or intraperitoneally (i.p.) and
12–16 hours later, the spleen was analyzed by flow cytometry.
Both routes of injection gave similar results.
Measuring cytokine production
DCs or NK cells were stimulated with 100 nM of Pam2
lipopeptides for 24 hours and the supernatants were measured for
IL-10 by ELISA (eBiosciences). CD4
+ T cells from OT II
transgenic mice were cultured with spleen DCs with or without
100 nM of Pam lipopeptides at the various doses of OVA peptide
for five days. The supernatants were measured for IL-10 by
ELISA. Serum from Pam2 lipopeptides treated mice or control
mice were taken one day after i.p. injection and were measured for
IL-10, INF-c, IL-4 and IL-17 by Cytometric Bead Array (BD
Bioscience). Analysis with the Cytometric Bead Array was
performed according to the manufacturer’s instructions.
Quantitative PCR
Total RNA was isolated with TRIzol (Invitrogen by life
technologies, Carlsbad, CA, USA), and reversed transcribed by
High Capacity cDNA Transcription Kit (ABI by life technologies,
Carlsbad, CA, USA) according to manufacturer instructions. The
qPCR was performed with the Step One Real-Time PCR system
(ABI). The primers used for real-time PCR have been reported
previously [29].
In vivo tumor challenge
Mice were s.c. injected with 223610
5 B16D8 cells into the
back. B16D8 melanoma is a NK-sensitive B16 melanoma cell line,
which we have previously established [22]. The tumor growth was
monitored twice a week. Sometimes mice were pre-treated with
Figure 5. NK-sensitive tumors grow slowly when Pam2CSK4 is
injected into T reg-depleted mice. (A) B6 mice were i.p. injected
with 500 mg of anti-CD25mAb (PC61) on day -3. The mice were
injected with B16D8 melanoma cells (2610
5) into their back on day 0.
Pam2CSK4 (10 nmol) or PBS was injected twice a week from day 0 to
day 14. Tumor growth was monitored twice a week. n=3 for each
group. A cross indicates the death of one mouse. One representative
experiments from two similar experiments is shown. (B) As in (A), but
the survival curve summarized from two separate experiments is
shown.
doi:10.1371/journal.pone.0018833.g005
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Then, 10 nmol of Pam2 lipopeptides or control saline was s.c
injected into footpad or i.p. injected twice a week. The both routes
of injection gave similar results.
In vitro suppression assay using T reg cells
The classical in vitro suppression assay was performed as
previously described [32,55]. Briefly, CD25
+CD4
+ T cells were
purified by flow cytometry and used as suppressor cells. CFSE-
labeled CD25
- CD4
+ T cells or CD4
+ T cells were stimulated with
or without anti-CD3 mAb (2C11) and 15–20 Gy irradiated spleen
cells. Various numbers of suppressor cells were added to the
culture. After three day culture, cells were stained with CD4 –PE
and dead cells were gated out with TOPRO-3 (Molecular Probes).
All cells in each culture were acquired using the FACS calibur (BD
Bioscience) to have the cell yield and number of live CFSE
+ cells/
culture was calculated. Analysis was performed with Flowjo
software (TreeStar, USA).
Supporting Information
Figure S1 NK cells up-regulates CD69 after systemic
injection of Pam2 lipopeptides. Mice were subcutaneously
injected with the indicated Pam2 lipopeptides (10 nmol) or saline.
After 16 hours, splenic NK cells were analyzed by flow cytometry.
Plots were gated on NK1.1
+ cells.
(TIF)
Figure S2 The frequency of T reg cells returns to
normal at day 7 after systemic injection of Pam2
lipopeptides. WT mice were i.p. injected with Pam2CSK4
(10 nmol). After seven days, spleen (Sp) and lymph node (LN) cells
were analyzed for the expression of Foxp3. The plots were gated
on CD4
+ T cells. One of two experiments is shown for the FACS
plots.
(TIF)
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